Premium
Recent progress in the development of polysaccharide conjugates of docetaxel and paclitaxel
Author(s) -
Roy Aniruddha,
Bhattacharyya Mousumi,
Ernsting Mark J.,
May Jonathan P,
Li ShyhDar
Publication year - 2014
Publication title -
wiley interdisciplinary reviews: nanomedicine and nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.175
H-Index - 72
eISSN - 1939-0041
pISSN - 1939-5116
DOI - 10.1002/wnan.1264
Subject(s) - taxane , paclitaxel , docetaxel , conjugate , drug , pharmacology , nanomedicine , biocompatibility , polysaccharide , drug delivery , chemistry , medicine , nanotechnology , chemotherapy , cancer , breast cancer , biochemistry , materials science , nanoparticle , mathematical analysis , mathematics , organic chemistry
Taxanes are one of the most potent and broadest spectrum chemotherapeutics used clinically, but also induce significant side effects. Different strategies have been developed to produce a safer taxane formulation. Development of polysaccharide drug conjugates has increased in the recent years because of the demonstrated biocompatibility, biodegradability, safety, and low cost of the biopolymers. This review focuses on polysaccharide–taxane conjugates and provides an overview on various conjugation strategies and their effect on the efficacy. Detailed analyses on the designing factors of an effective polysaccharide–drug conjugate are provided with a discussion on the future direction of this field. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease